RDY today
$14.73-$0.11 (-0.74%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourExpanding
1 hourSymmetric Triangle
15 minStrong Bearish
5 minBearish
Daily trend turns up above $15.67
Key levels
Resistance$15.67
Resistance$15.08
Support$14.72
Support$14.05
Latest news & SEC filings
ProductDr. Reddy's gets Brazilian approval for generic Ozempic
ProductDr. Reddy's Laboratories makes a copy of lenacapavir through a worldwide access deal
All RDY news →About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories is an Indian drugmaker that develops, makes, and sells generic prescription medicines, branded formulations, biosimilars, and nonprescription health products. It also produces active pharmaceutical ingredients and intermediates and provides contract research and manufacturing services to other pharmaceutical and biotechnology firms. Its main markets are the United States, India, Russia and nearby countries, and Europe, serving patients, physicians, pharmacies, distributors, and business partners.
Based on the company's 20-F filed May 29, 2026.
NYSE · Healthcare
DR REDDYS LABORATORIES LTD (RDY)
What Is the Price Target for RDY?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is RDY a Buy or Sell Right Now?
Thesis
- •Revenue growing 14.2% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RDY.
Start Free Trial →Is RDY Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward
Fair Value
$776.80
63
Moat Score
NARROW
2/9
Piotroski Score
6.2
Altman Z-Score
What Is Smart Money Doing with RDY?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RDY Growth Story
Revenue YoY
14.2%
3yr Revenue CAGR
10.2%
EPS Growth YoY
-0.64%
FCF Growth YoY
-36.2%
Revenue Trend
ACCELERATING
Dark Pool Trades for RDY
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RDY, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:31:45 | $14.73 | 91,164 | $$1.3M | BUY |
| 22:12:16 | $14.73 | 91,783 | $$1.4M | BUY |
| 21:27:07 | $14.73 | 2,958 | $$44K | BUY |
| 21:00:12 | $14.73 | 2,965 | $$44K | BUY |
| 21:00:02 | $14.73 | 1,300 | $$19K | BUY |
5 dark pool trades shown · $$2.8M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for RDY
PREVIEWSEPT Investing provides real-time options flow tracking for RDY, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $22.5 | Dec 18 | 36 | $$10 | 2 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About RDY
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for RDY. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $RDY -- Bearish Bounced back with 88% buying after prior session selling. Uptrend holds while above $12.96. $14 psychological level is the next resistance to watch. The Play: Watch for...
Join 3,500+ traders discussing RDY in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for DR REDDYS LABORATORIES LTD (RDY) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RDY — frequently asked questions
What is RDY stock price today?
DR REDDYS LABORATORIES LTD (RDY) is at $14.73, down 0.74% (-$0.11) at the Nov 12, 2026 close.
Why is RDY stock moving today?
Latest RDY news — Nov 5, 2026: Dr. Reddy's gets Brazilian approval for generic Ozempic · Nov 3, 2026: Dr. Reddy's Laboratories makes a copy of lenacapavir through a worldwide access deal
What do analysts rate RDY?
Analyst ratings for RDY: 2 Buy, 0 Hold, 0 Sell — consensus Buy.
Did RDY beat earnings?
RDY last reported on Oct 23, 2026: EPS $0.12 vs $0.09 expected — a beat of 26.8%.
Does RDY pay a dividend?
Yes. RDY's dividend yield is 0.71%.
How much debt does RDY have?
DR REDDYS LABORATORIES LTD reported $102M of debt and $172M of cash (Mar 31, 2025).
What are RDY support and resistance levels?
Support: $14.72, $14.05, $13.47. Resistance: $15.08, $15.67, $16.17.
What are insiders doing with RDY?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on RDY?
Nov 5, 2026: Dr. Reddy's gets Brazilian approval for generic Ozempic · Nov 3, 2026: Dr. Reddy's Laboratories makes a copy of lenacapavir through a worldwide access deal